Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Screening Protein Predictive of Response to Tumor Necrosis Factor-α Inhibitors Treatment in Chinese Rheumatoid Arthritis From "Real World" and Investigating Its Mechanism Through Signal Pathway

NCT02878161 is registered in ClinicalTrials.gov with Fen Li as lead sponsor.

NCT NCT02878161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02878161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Screening Protein Predictive of Response to Tumor Necrosis Factor-α Inhibitors Treatment in Chinese Rheumatoid Arthritis From "Real World" and Investigating Its Mechanism Through Signal Pathway
Lead sponsor
Fen Li
Phase
Phase 4
Overall status
Unknown status
Start date
January 31, 2016
Completion date
December 31, 2019
Enrollment
240 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis